Dietary B vitamin and methionine intake and MTHFR C677T genotype on risk of colorectal tumors in Lynch syndrome: the GEOLynch cohort study.
Audrey Y Jung, Fränzel J B van Duijnhoven, Fokko M Nagengast...
https://pubmed.ncbi.nlm.nih.gov/24916333/Actively Recruiting
Led by Wageningen University · Updated on 2017-10-06
1000
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are studying people with Lynch syndrome, a genetic condition caused by mutations in certain DNA mismatch repair genes such as MLH1, MSH2, MSH6, PMS2, or EPCAM. This condition raises the risk of several cancers, especially colorectal and endometrial cancer. The GEOLynch cohort study aims to understand how genetic, environmental, and other factors influence tumor risk in these individuals. Participants provide detailed information through questionnaires about their diet, supplement use, physical activity, weight, height, and medication. Initially, participants gave buccal swabs for DNA analysis, but since 2012 new participants donate blood samples, which are stored for future research. Medical records and pathology reports are regularly reviewed about every two years to track tumor diagnoses and colonoscopy results. Participants are involved in ongoing follow-up, including repeated questionnaires and sample donations for biomarker and genetic analyses. The study measures colorectal, endometrial, and overall cancer diagnoses by reviewing medical documentation approximately every two years. This long-term observation helps researchers calculate risks and understand how different factors affect tumor development in people with Lynch syndrome.
CONDITIONS
The GEOLynch Cohort Study
F
Fränzel van Duijnhoven, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Wageningen University
Lead Sponsor
Wereld Kanker Onderzoek Fonds
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to approximately 24 years
Participants who undergo routine care are observed. Clinical characteristics regarding performed colonoscopies and tumour diagnoses are gathered from medical records and pathology reports approximately every 2 years.
Assessments approximately every 2 years
Duration - Ongoing throughout study participation
Participants complete questionnaires about diet, physical activity, weight, height, and medication use. Biological samples such as buccal swabs or blood samples are collected for genetic and biomarker analyses.
Questionnaires and sample donation at baseline and follow-up visits
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Audrey Y Jung, Fränzel J B van Duijnhoven, Fokko M Nagengast...
https://pubmed.ncbi.nlm.nih.gov/24916333/Fränzel J B van Duijnhoven, Akke Botma, Renate Winkels...
https://pubmed.ncbi.nlm.nih.gov/23657759/Renate C Heine-Bröring, Renate M Winkels, Akke Botma...
https://pubmed.ncbi.nlm.nih.gov/23825568/Akke Botma, Fokko M Nagengast, Marieke G M Braem...
https://pubmed.ncbi.nlm.nih.gov/20733131/Renate M Winkels, Akke Botma, Fränzel J B Van Duijnhoven...
https://pubmed.ncbi.nlm.nih.gov/22062356/Akke Botma, Hans F A Vasen, Fränzel J B van Duijnhoven...
https://pubmed.ncbi.nlm.nih.gov/23254892/Wageningen University
Lead Sponsor
Wereld Kanker Onderzoek Fonds
Collaborating Sponsor